Insmed reported $218.28M in Ordinary Share Capital for its fiscal quarter ending in June of 2026.





Ordinary Share Capital Change Date
BioMarin Pharmaceutical USD 193.54M 267K Jun/2026
Cytokinetics USD 124.43M 2.17M Mar/2026
DBV Technologies USD 235.6M 98.78M Dec/2025
Gilead Sciences USD 1.24B 1000K Jun/2026
Heron Therapeutics USD 188.31M 4.99M Dec/2025
Insmed USD 218.28M 1.76M Jun/2026
Novartis USD 1.91B 60K Mar/2026
Regeneron Pharmaceuticals USD 105M 300K Mar/2026
Sarepta Therapeutics USD 105.62M 53K Jun/2026
Ultragenyx Pharmaceutical USD 98.3M 1.7M Mar/2026
Vertex Pharmaceuticals USD 253.3M 900K Jun/2026